The Medtronic transfer pricing case is a long-running dispute over whether Medtronic charged its Puerto Rican manufacturing subsidiary a fair royalty for the right to use the parent company’s patents and manufacturing know-how. The IRS says the royalties were too low, leaving roughly $548 million in unpaid federal tax for 2005 and $810 million for 2006. After two Tax Court decisions and two reversals by the U.S. Court of Appeals for the Eighth Circuit, the case was sent back for a third trip through the Tax Court in September 2025.
What the Dispute Is About
Medtronic’s U.S. parent licensed patents, trade secrets, manufacturing know-how, and regulatory approvals to Medtronic Puerto Rico Operations Co. (MPROC), which manufactured cardiac pacemakers, defibrillators, and related devices. MPROC paid royalties back to the U.S. parent for those licenses. Because Puerto Rico offered far lower tax rates than the mainland, the lower those royalty payments, the more profit stayed with MPROC and the less Medtronic owed in U.S. federal tax.
The IRS audited Medtronic’s 2005 and 2006 returns and concluded the royalty rates were below what unrelated companies would have negotiated. Section 482 of the Internal Revenue Code gives the IRS authority to reallocate income between related businesses when their pricing doesn’t reflect what independent parties would have agreed to, and it requires that income from transfers of intangible property be “commensurate with the income attributable to the intangible.”1Office of the Law Revision Counsel. 26 USC 482 – Allocation of Income and Deductions Among Taxpayers The Treasury Regulations turn that into the “arm’s length standard”: a controlled transaction meets the standard when its result matches what unrelated parties would have reached under the same circumstances.2eCFR. 26 CFR 1.482-1 – Allocation of Income and Deductions Among Taxpayers
The parties agreed on the corporate structure. They disagreed sharply on how to price the licenses.
The Two Competing Methods
Medtronic relied on the Comparable Uncontrolled Transaction (CUT) method, which prices a related-party deal by reference to a similar deal between unrelated parties. Its benchmark was a 1992 patent licensing agreement with Pacesetter, a competitor, that came out of a patent infringement settlement. Pacesetter was unrelated to Medtronic, so the deal was negotiated at arm’s length. Medtronic argued it covered similar technology and could serve as a reliable comparable for the MPROC licenses.
The regulations impose a specific condition on that argument: the intangible property in the comparable transaction must have “similar profit potential” to the intangible property in the controlled transaction.3eCFR. 26 CFR 1.482-4 – Methods to Determine Taxable Income in Connection With a Transfer of Intangible Property That requirement became the pressure point in the case.
The IRS proposed the Comparable Profits Method (CPM) instead. Rather than comparing specific transactions, the CPM looks at whether a subsidiary’s overall profit level is consistent with profits earned by independent companies performing similar functions. Under the IRS’s analysis, MPROC was closer to a contract manufacturer entitled to a routine return, with most of the profit flowing back to the U.S. parent.
Neither method has automatic priority. Under the “best method rule,” the arm’s length result is determined under whichever method provides the most reliable measure given the facts and available data.2eCFR. 26 CFR 1.482-1 – Allocation of Income and Deductions Among Taxpayers The Tax Court was free to reject both parties’ preferred approaches, and it did.
Court History
Medtronic I: Tax Court, 2016
In its first decision, the Tax Court found that the CUT method was the best approach but made significant adjustments to the Pacesetter agreement to account for differences between the two transactions. The result was a profit split of roughly 54% to Medtronic’s U.S. affiliates and 46% to MPROC, a far more favorable outcome for Medtronic than the IRS wanted.
Eighth Circuit Remand, 2018
The IRS appealed, and in 2018 the Eighth Circuit vacated the decision without resolving the merits. The appellate court found that the Tax Court’s factual findings were too sparse to support meaningful review and sent the case back for a fuller explanation of the reasoning.4Justia Law. Medtronic, Inc, etc. v. CIR, No. 23-3063 (8th Cir. 2025)
Medtronic II: Tax Court on Remand, 2022
On remand, the Tax Court again rejected both the CUT method and the CPM. This time it developed what it called an “unspecified method” that blended elements of both, arriving at a wholesale royalty rate of 48.8% for both tax years. The revised split gave roughly 69% of the profit to U.S. affiliates and 31% to MPROC, shifting more income to the U.S. parent than the first decision had.
Eighth Circuit Remand Again, September 2025
The Eighth Circuit vacated the Tax Court’s order a second time in September 2025, and this ruling was more pointed. The court identified substantive errors rather than a mere failure to explain.4Justia Law. Medtronic, Inc, etc. v. CIR, No. 23-3063 (8th Cir. 2025)
On the Pacesetter agreement, the appellate court agreed with the Tax Court that the Pacesetter license and the MPROC licenses did not have similar profit potential. The Pacesetter deal covered only patents, while the MPROC licenses encompassed the “full array of intangible property,” including manufacturing know-how and regulatory approvals. Because the similar-profit-potential requirement wasn’t met, the court held the Pacesetter agreement could not provide reliable data for pricing the MPROC licenses under any method.4Justia Law. Medtronic, Inc, etc. v. CIR, No. 23-3063 (8th Cir. 2025)
On the CPM, the court found the Tax Court had overemphasized product similarity when it rejected the IRS’s proposed comparable companies. The regulations specifically say the CPM is less dependent on product similarity than transaction-based methods. The Tax Court had also failed to make adequate findings on several key issues: the differences in asset bases between MPROC and the proposed comparables, the specific functions each entity performed, and the amount of product liability risk MPROC actually bore. The case was sent back with instructions to reconsider the IRS’s CPM under the correct legal standard and to make detailed factual findings on each of those points.
Where the Case Stands Now
The 2025 decision reshapes the fight in two ways. Medtronic’s primary defense, the Pacesetter agreement, has been definitively ruled out. And the Tax Court has been told to take a harder look at the IRS’s approach under the correct legal test. That does not guarantee the IRS wins on remand; the CPM still has to survive scrutiny, and the Tax Court’s findings on assets, functions, and risk will shape the outcome. The dollar amounts at stake, roughly $1.4 billion in tax across just two years, remain unchanged.
What It Means for Other Multinationals
The Eighth Circuit’s ruling matters beyond Medtronic. Companies that license broad bundles of intellectual property to foreign affiliates but benchmark their royalties against narrower arm’s length agreements now face a clearer standard: the comparable transaction has to reflect similar profit potential, and a patent-only deal will struggle to justify royalties on a license that also transfers manufacturing know-how, trade secrets, and regulatory approvals. The court’s treatment of the CPM also signals that functional comparability, not close product matching, is what counts when the IRS builds a case on profit-level benchmarks.
The regulations reward companies that document their pricing decisions when the return is filed. Contemporaneous documentation that identifies the method chosen, explains why alternatives were rejected, describes the comparable transactions or companies used, and lays out the economic analysis can shield a taxpayer from accuracy-related penalties under Section 6662, which can otherwise reach 20% or 40% of the underpayment on large transfer pricing adjustments.5Office of the Law Revision Counsel. 26 U.S. Code 6662 – Imposition of Accuracy-Related Penalty on Underpayments6eCFR. 26 CFR 1.6662-6 – Transactions Between Persons Described in Section 482 and Net Section 482 Transfer Price Adjustments
Companies that want certainty before a dispute arises can negotiate an Advance Pricing Agreement through the IRS’s Advance Pricing and Mutual Agreement Program, which fixes the transfer pricing method for specified transactions, typically over a five-year term.7Internal Revenue Service. Advance Pricing and Mutual Agreement Program APAs take time and resources to negotiate. For a company routing billions of dollars through a single licensing structure, the Medtronic docket is a working illustration of the alternative.